summary Aim : The aim of the study was to describe the frequency of anti-phosphatidylserine-prothorombin antibody(aPS/ PTAb) in patients with recurrent abortion and preeclampsia, and to study the relationship between the presence of aPS /PTAb and clinicalˆnding. Eighty six cases of recurrent abortion and 82 cases of preeclampsia were studied. A aPS/ PTAb was measured by an enzyme linked immunosorbent assay(ELISA).
Introduction
Anti-phospholipid antibodies are a family of antibodies that include the lupus anticoaglant(LA) and anti-cardiolipin antibodies deˆned by Sapporo criteria. 1) Prothrombin wasˆrst described as a cofactor for a circulating anticoagulant in patients with systemic lupus erythematosis(SLE) by Loeliger et al. 2) Prothrombin binds to negativery charged phospholipids through g carboxy glutamic acids(GLA) domains. 3) The LA activity was also identiˆed as a binding reactivity to phospholipid-protein complexes, especially complexes of phospholipids and prothrombin. 4) There are 2 kinds of methods to detect anti-prothrombin antibodies.
Recently, it has been reported the enzyme-linked immunosorbent assays(ELISA) that detect of antibodies(aPS/PTAb) against phosphatidylserine (PS) prothrombin(PT) complex correlate more signiˆcantly with the clinical manifestations of antiphospholipid antibody syndrome(APS) in systemic autoimmune disease patients, than do the ELISA detecting antibodies directed to prothrombin bound on irradiated plates. 5) The association of aPS/PTAb with venous or arterial thrombosis has been reported. 6) Galli et al. have reported the literature regarding aPS/PTAb as a diagnostic criteria for arterial and venous thrombosis in the APS. 7) The presence of APAs has been reported in habitual abortion of unknown etiology and unexplained intrauterine fetal death. 8) By histological examination of the placentas obtained from preeclamsia patients, infarction andˆbri-noid necrosis have been detected. 9) These changes seem to be similar to theˆndings concerning placenta taken from APA positive pregnancies. 8) In patients with preeclampsia, the high incidence of placental dysfunctions and intrauterine growth restriction (IUGR) have been reported. 10) APAs have been known to bind to vascular endotherial cells and platelets. It has been proposed that the functions of APAs are to prevent protein C activation and to enhance platelet aggregation which might cause abnormal coagulation and platelet agglutination without changes in prostacyclin production from endothelial cell. 11, 12) If aPS/PTAb have the ability to bind villous trophoblasts, aPS/PTAb might cause placental dysfunctions.
We tried toˆnd the frequency of aPS/PTAb in patients with recurrent abortion and preeclampsia and to study the relationship between the presence of aPS/PTAb and clinicalˆndings.
Materials and Methods
Sample collection
Serum samples were taken from 86 cases of recurrent abortion, including 52 cases of the experience of 2 miscarriages, 34 cases of 3 times and more recurrent miscarriages, and from 47 healthy nonpregnant women. In study cases, uterine abnormalities, infection, abnormal antibodies involving blood types and chromosomal abnormality were excluded. Eight cases of systemic autoimmune disease patients were included. Eighteen cases showed APA positive such as anticardiolipin antibody, anti b 2  GPI antibody and LA.
In preeclampsia study, serum samples were taken from 82 cases of preeclampsia, including 51 cases of the severe type, 31 cases of the mild type and from 40 normal pregnant women of 20 to 40 weeks of gestation. The grade of preeclampsia was classiˆed according to the criteria of the Japanese Society of Obstetrics and Gynecology. No signiˆcant diŠerence between 82 cases of preeclampsia and 40 cases of normal pregnancies was found in age, gravity and gestational week.
Measurement of anti-phosphatidylserine-
prothrombin antibody (aPS/PTAb) A aPS/PTAb were measured by ELISA developed by Matsuda et al. 13) PS (L a phosphatidy L serine, SIGMA P 6641) was coated onto 96 well microplates (Poly soap Immuno Plate, NUNC) by evaporation. The plates were blocked Ca Tris buŠered saline (TBS ; 10 mM TBS, PH 7.4 7.5 concluding 5 mM Calcium Chloride) with 1％ bovine serum albumin(BSA). The microplates were incubated for 120 minutes at room temperature and washed 2 times with Ca TBS including 0.05％ Tween 20. Then, 100 ml of serum samples or standard diluted 1：50 in BSA Ca TBS with human PT diluted 1：50 in Ca TBS were added to the wells.
The microplates were incubated for 90 minutes at room temperature and washed 3 times with Ca TBS including 0.05％ Tween 20. A peroxidase conjugated anti-human IgG or IgM antibody (Alkaline phosphatase-conjugated goat anti-human IgM and IgG, ZY laboratory) was added to each well and incubated for 1 hour at room temperature. After washing 3 times by Ca TBS including 0.05％ Tween 20, 100 ml of p nitrophenylphoshate (ICN) was added and incubated for 10 minutes. The reaction discontinued by the addition of 3N NaOH. The optical density (OD) of each well was read at 405 nm using a microplate reader (BIO RAD Model 550). As standards of these measurements, 2 kinds (IgG and IgM) of high-titer serum obtained from patients with APS were used. The standard curves for the aPS/PTAb (IgG and IgM) were proportional in the dilution of standards from 50 times to 12800 times (IgM) or from 800 times to 51200 times (IgG) respectively. The titers were set on 1000 U/ml for 50 times dilution of IgG and IgM. The cut oŠ OD values (mean＋3SD) were determinated as : 4.9 for aPS/PTAb IgG and 13.3 for aPS/PTAb IgM in healthy nonpregnant women and as 13.2 for aPS/PTAb IgG and 7.3 for aPS/ PTAb IgM in normal pregnant women.
Statistical Analysis
Titers between groups were compared with unpaired t test. Positive rates for 2×2 tables were compared using Fisher's exact test. A P value＜0.05 (two sided) was considered statistically signiˆcant. Table I) The Values (mean±SD) of aPS/PT IgG and IgM antibody in non-pregnant women(n＝16) were 2.07 ±0.95, 8.05±1.76, respectivery. The cut oŠ value were decided as 4.9 for IgG antibody and 13.3 for IgM antibody. In aPS/PTAb IgG antibody measurements, 3 out of 86 cases (3.4％) were positive for aPS /PTAb. In aPS/PTAb IgM antibody measurements, When the relationship between aPS/PTAb and anti b 2  GPI antibody was evaluated, only one of 3 positive aPS/PTAb was positive for anti b 2  GPI antibody.
3. The frequency of aPS/PTAb in early and late fetal abortion.
When the frequency of aPS/PTAb in the early or late abortion was evaluated, 6 out of 74 cases (8.1％) were positive for aPS/PTAb in recurrent embryonic losses at early fetal period (＜10 weeks' gestation) and 2 out of 12 cases (16.6％) were positive for aPS/ PTAb in recurrent abortion at late fetal period (＞10 weeks' gestation).
No signiˆcant diŠerence was found between early and late fetal abortion (p＝0.40).
4. aPS/PTAb in preeclampsia cases. (Fig. 2 , Table II) The Values(mean±SD) of aPS/PT IgG and IgM antibody in normal pregnant women(n＝16) were 6.56±2.21, 2.99±1.43, respectivery. The cut oŠ value were decided as 13.2 for IgG antibody and 7.3 for IgM antibody. In aPS/PTAb IgG antibody measurements, 2 out of 82 cases (2.5％) were positive for aPS/PTAb. In aPS/PTAb IgM antibody measurements, 13 out of 82 (16％) were positive for aPS/ PTAb. The incidence of IgM or total aPS/PTAb in preeclampsia cases was higer than that of 40 normal pregnant women (p＝0.005, p＝0.002).
5. Values and positive rates of aPS/PTAb in severe or mild preeclampsia cases (Table III) The values (mean±3SD) and positive rates of aPS /PTAb in patients with severe preeclampsia (9.9± 24.2, 21.5％) was higher tendency than in patients with mild preeclampsia (5.1±1.7, 6.4％, p＝0.117).
6. Values and positive rates of aPS/PTAb in preeclampsia cases with or without proteinuria (Table  IV) The values(mean±3SD) and positive rates of aPS/ PTAb in proteinuria-positive cases (6.2±3.8, 16.9 ％) was higher tendency than in patients with proteinuria-negative cases (5.0±1.5, 4.3％, p＝0.098).
7. Values and positive rates of aPS/PTAb in preeclampsia cases with or without hypertension (Table V)
The values (mean±3SD) and positive rates of aPS /PTAb in hypertension-positive cases (8.3± 19.9,21.0％) was higher tendency than in patients with hypertension-negative cases(5.1±1.8, 4.0％, p ＝0.096).
8. Values and positive rates of aPS/PTAb in (Table VI) The Values(mean±3SD) and positive rates of aPS /PTAb in severe hypertension-positive cases (10.1± 25, 23.0％)was higher than in hypertension-negative cases (5.1±1.9, 4.0％, p＝0.045). The value was statistically signiˆcant.
9. Values and positive rates of aPS/PTAb in preeclampsia cases with or without IUGR (Table VII,  Table VIII) The evaluation of IUGR was done by Nishida's deˆnition. Incidence of IUGR in all cases of preeclampsia was 35.3％. There were no signiˆcant diŠerence between preeclampsia with and without IUGR concerning to age, gravity and mean of gestational week. Mean of neonatal body weight in preeclampsia cases without IUGR (2302±794) was greater than in preeclampsia cases with IUGR (1696 ±570) (p＝0.002). These incidence in aPS/PTAb positive and aPS/PTAb negative cases were 6.8％ and 24.5％, respectively (p＝0.072). No signiˆcant relationship was found in positive rate of aPS/PTAb between preeclampsia with and without IUGR.
Discussion
Our results indicated that the both IgG and IgM types of aPS/PTAb were found in patients with recurrent abortion and preeclampsia, which were not related to anti b 2  GPI antibodies, gestational weeks of abortion, severity of preeclampsia, occurrence of IUGR, but related to only severe hypertension in preeclampsia patients. This may be related to the limited number of sample size, but the relation between aPS/PTAb and severe hypertension is very interesting.
Many kinds of methods to detect the antiprothrombin antibodies have been developed. In our study, a modiˆcation of the ELISA described by Matsuda was used to detect aPS/PTAb. We found the presence of IgG or IgM aPS/PTAb in patients with recurrent abortion. Incidence of aPS/PTAb IgG(3.4％) was lower than those of anticardiolipin antibody(10.4％) and antiphosphatidylserine antidoby(4.6％) and b 2  GPI antibody(4.6％) in our laboratory. Tsutsumi could not identify aPS/PTAb in a population of patients with unexplained miscarriges. 14) They studied 86 consecutive patients with history of 2 or more recurrent miscarriges. However, patients with history of overt thrombotic events were not included. The titer of IgG, IgM and IgA aPS/PTAb were measured by ELISA. Cut-oŠ levels were set at mean＋5SD, established using sera from 36 healthy volunteers. 14 In our cases, there was one patients with history of overt thrombotic events. In our study, when the cut-oŠ levels were set at mean＋5SD, only one case of IgM Ab became positive without statistical signiˆcance. Therefore, the determination of the cutoŠ point is quite important. Forasttiero et al. reported that presence of IgG and/or IgM anti-prothrombin antibodies had no signiˆcant relationship with obstetric complications. 15) However, Ailus et al. found that secondary aborters tended to have higher level of IgG anti-prothrombin antibodies(aPTAb) than did the primary aborters, and suggested that presense of this antibody may contribute to the development of placental thrombosis. 16) A aPS/PTAb is a diŠerent type of antibody from aPTAb. We suggest same kind of pathogenesis in aPS/PTAb because a part of aPS/ PTAb could be detected as aPTAb.
In systemic autoimmune disease, Atsumi found 10.9％ positivity of aPS/PTAb for IgG class, and 4.9 ％ for IgM class. 5) In our cases, 8 cases of systemic autoimmune disease patients were included. In cases of systemic autoimmune disease patient, 1 of 8 cases (12.5％) was positive with almost same frequency.
The aPS/PTAb IgM in recurrent abortion was much more detected than IgG antibody. The distribution of aPS/PTAb IgM is diŠerent from that of systemic autoimmune disease by Atsumi. 5) This might be able to explained by local event in recurrent abortion for systemic autoimmune disease because IgM autoantibodies are switched to IgG antibody according to progression of disease. 17) The pathological mechanism of aPS/PTAb has not been known well. Prothrombin deˆcient mice showed that pothrombin deˆciency in the models lead to partial embryonic fatality as a result of bleeding in the york sac cavity and tissue necrosis of the embryos. 18) It seems to be speculated that the decrease of prothrombin caused by antiprothrombin antibodies in patients with the APS might lead to the same fatal changes in the development of the fetal life. 19) Either aPTAb or aPS/PTAb may cause the decrease of prothrombin and may prevent the maintenance of pregnancy. A small group of recurrent abortion seems to be related to aPS/PTAb because a part of aPS/PTAb is detected as aPTAb.
It has been reported that there is a diŠerent pathological mechanism between the early and late abortion. 20) In anti-phosphatidylethanolaine antibody (aPEAb) positive cases, higher frequency of the early abortion has reported. 20) When the frequency of the early and late abortion were evaluated, no signiˆcant diŠerence was found between early and late fetal abortion. We think that A aPS/PTAb is a diŠerent type of antibody from aPEAb.
Akimoto et al. examined the levels of IgG autoantibodies against prothrombin in pregnant women. 21) Ten(36％) of the 28 women with severe preeclampsia were positive for antiprothrombin antibodies as compared with 3(9％) of the 36 women with normal pregnancies. In our cases, 11(21.5％) of the 51 women with severe preeclampsia were positive. Our positive rate was lower than that of them. It may depend on methodological diŠerence to detect antibodies against prothoronbin. Our data shows that a aPS/PTAb is a diŠerent type of antibody from aPSAb. Our results suggest that there may be a speciˆc relation between aPS/PTAb and preeclampsia.
We have reported the presence of various kinds of antiphospholipid antibody in preeclampsia. 10) The prevalence of anticardiolipin and antiphosphatidylserine antibody (aPSAb) were 14.7％ and 18.1％, respectively. Though aPS/PTAb is a diŠerent antibody from aPSAb, the positivity (18.2％) of aPS/ PTAb was same as that of aPSAb. It may be depend on the deŠerence of method. In previous assay, Loizou method was used. 22) However, the prevalence of IgG anticardiolipin, aPSAb and anti b 2  GPI antibody were 10.0％, 18.1％, and 18.4％, respectively. The value(2.5％) of aPS/PTAb IgG was lower than those of the 3 antibodies. The prevalence of IgM anticardiolipin and antiphosphatidylserine were 14.7％ and 0％, respectively. The positivity(16.0％) of aPS/ PTAb IgM was higher than those of the 2 antibodies. Ourˆnding seems to show that a aPS/PTAb is a diŠerent type of antibody from these antibodies including aPSAb.
We analyzed the relationships between clinicalˆnd-ing of preeclampsia and aPS/PTAb. The prevalence of aPS/PTAb in severe cases was much higher than that of mild cases. In cases of severe hypertension, signiˆcant higher prevalence was found as compared with normal pregnancies. We have already reported the presence of antiphosphatidylserine antibody (aPSAb) in preeclampsia. A aPSAb positivity in severe cases (22.7％) was greater than that in mild cases (9.1％). 10) A aPS/PTAb seems to be much more related to severity of preeclampsia and hypertension.
The presence of IUGR in antiphospholipid antibodies has been reported. 10, 23) In this study, there was no relationship between aPS/PTAb positivity and IUGR. In our previous study, the incidence of IUGR in IgG anticardiolipin antibody(ACA) positive, IgM ACA positive and IgG aPSAb positive cases was 43 ％, 40％, and 50％, respectively. Sletnes et al. reported that the frequency of IUGR in anticephalin antibody positive women(57.1％) was signiˆcantly higher compared with the negative. 23) In anti b 2  GPI antibodies, that of IUGR was 43％. The incidences in positive cases were higher than that in negative cases. A aPS/PTAb dose not seem to relate the IUGR of preeclampsia. The pathogenic ability of aPS/PTAb may be diŠerent from ACA, aPSAb and anti b 2  GPI antibodies.
Coagulation changes such as increased levels of the thrombin anti-thrombin III complex (TAT) and the plasminogen inhibitor complex (PIC) in preeclampsia have been demonstrated. 24) These changes in preeclampsia might be related to these antibodies. We have already reported the relationship between the anti-cardiolipin antibody and prolonged activated partial thromboplastin time (APTT) and low platelet counts. 10) In our study, TAT was measured in 3 cases of aPS/PTAb positives. All cases showed high values such as 25.1, 12.0 and 8.2 ng/ml. We speculate that aPS/PTAb may play a role of coagulation changes in preeclampsia.
We concluded that aPS/PTAb appears in some cases of recurrent abortion and preeclampsia. Our data suggest that aPS/PTAb might be a risk factor in patients with recurrent abortion, and might relate to clinicalˆnding in preeclampsia.
